Current projects

Safety en tolerability of EA-230

Aim and methods: The goal of this randomized, double-blind, placebo-controlled study is to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of the novel compound EA-230, a newly developed compound which is derived from the human chorionic gonadotropin hormone (hCG). This iss conducted in a phase 1 trial followed by a phase 2a trial using the experimental human endotoxemia model in 36 healthy human volunteers.


 

See the overview of studies (mostly "trials") in which you can participate as a healthy person or as a patient with a disorder.

Please note that more studies may be available for participation, but only in Dutch.

Studies for which registration has already closed or which have been fully completed but are still available for viewing can be found here.

Results (5)

Filter results